Point Therapeutics says PT-630 reduces triglycerides

By Elaine Rigoli

Tampa, Fla., June 12 - Point Therapeutics, Inc. said single-dose acute studies of PT-630 and the CP-inhibitor showed PT-630 increased insulin secretion, reduced glucose excursion and increased GLP-1 levels at similar levels to the CP-inhibitor in animals.

However, even with a single-dose administration, PT-630 demonstrated longer-term benefits in both elevation of GLP-1 levels and lowering of plasma glucose at later times than the CP-inhibitor, according to a news release.

Point Therapeutics is a Boston-based biopharmaceutical company developing a portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and as vaccine adjuvants.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.